[Skip to Content]
[Skip to Content Landing]
December 1974

Effectiveness of Trioxsalen Therapy for Vitiligo

Author Affiliations

Panaji 403 001 Goa, India

Arch Dermatol. 1974;110(6):957-958. doi:10.1001/archderm.1974.01630120089029

To the Editor.—  The recent publication by Kaidbey and Kligman1 is welcomed, for it effectively provides an answer to the controversies raised earlier by Kligman and Goldstein.2 It was difficult to accept the hasty conclusions drawn by the latter authors, and I had, in turn, doubted3 their illconceived observation on nonabsorption of trioxsalen from the gastrointestinal tract, the very basis for using this drug therapy in cases of vitiligo.4-7In fact, Kligman and Goldstein2 explained the lack of phototoxic responses when the recommended doses of 10 to 20 mg of trioxsalen were administered. The observations of the earlier workers4-7 were actually based on therapeutic effectiveness and not on phototoxicity. How psoralen works in vitiligo is still unknown, and I wonder whether any of them4-7 tried to explain the action of this product. But, repigmentation of vitiliginous patches occurs after repeated exposures to

First Page Preview View Large
First page PDF preview
First page PDF preview